Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches
- 30 April 2009
- journal article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 36, S27-S35
- https://doi.org/10.1053/j.seminoncol.2009.02.007
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences of the United States of America, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- The Epigenomics of CancerCell, 2007
- Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALKProceedings of the National Academy of Sciences, 2007
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Proceedings of the National Academy of Sciences, 2006
- Validating Stat3 in cancer therapyNature Medicine, 2005
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004